Pharmaceutical Research and Technology Laboratories, Astellas Pharma Inc., Shizuoka 425-0072, Japan.
J Pharm Sci. 2013 Sep;102(9):3128-35. doi: 10.1002/jps.23484. Epub 2013 Mar 4.
The aim of this study was to find out polymeric compounds that can inhibit the interaction between YM466, a novel anticoagulant, and bile to improve its oral bioavailability. In vitro ultrafiltration method using extract gall powder was useful to detect the formation of insoluble complex of YM466 with bile and also used to select a polymer that can inhibit the interaction between YM466 and bile. The in vitro studies revealed that aminoalkylmethacrylate (AAM) copolymer E, a polymethacrylate, dose-dependently inhibited the interaction between YM466 and bile and that this polymer could interact with bile salt, but not with YM466, possibly by electrostatic and/or hydrophobic interactions. The coadministration of AAM copolymer E with YM466 to rats dose-dependently increased the plasma concentration of YM466 and it was found that the oral dose of the polymer three times of YM466 (polymer to drug ratio in weight, P-D ratio, 3) significantly increased AUC0-1 h of YM466 to 2.6-fold of that of YM466 alone. Considering the condition of therapeutic use of YM466 and the maximum tolerated dose of the polymer, the formulation of P-D ratio 3 would be clinically practical and promising from the viewpoint of safety.
本研究旨在寻找能抑制新型抗凝剂 YM466 与胆汁相互作用的聚合物,以提高其口服生物利用度。采用提取的胆粉进行体外超滤法,可用于检测 YM466 与胆汁形成不溶性复合物,也可用于选择能抑制 YM466 与胆汁相互作用的聚合物。体外研究表明,聚甲基丙烯酸氨乙酯(AAM)共聚物 E 作为一种多甲基丙烯酸酯,能剂量依赖性地抑制 YM466 与胆汁的相互作用,该聚合物可能通过静电和/或疏水相互作用与胆汁盐相互作用,但与 YM466 不相互作用。将 AAM 共聚物 E 与 YM466 同时给予大鼠,可剂量依赖性地增加 YM466 的血浆浓度,研究发现,聚合物的口服剂量是 YM466 的 3 倍(聚合物与药物的重量比,P-D 比为 3),可使 YM466 的 AUC0-1h 增加到单独给予 YM466 的 2.6 倍。考虑到 YM466 的治疗用途和聚合物的最大耐受剂量,从安全性角度来看,P-D 比 3 的配方具有临床实用性和广阔前景。